8-K: INmune Bio reprices options, sets CTAD talks

Shareholders approve a one-time option repricing to $1.50 and the company schedules two Alzheimer’s presentations at CTAD 2025.

Summary

• Shareholders approved a one-time repricing of certain outstanding employee, executive, and director stock options to an exercise price of $1.50 per share, effective November 18, 2025.
• Up to 5,511,000 options under the 2017, 2019, and Second Amended and Restated 2021 Stock Incentive Plans are eligible for repricing; all other terms, including vesting and term, remain unchanged.
• Voting results on the Option Repricing Proposal: For 7,144,433; Against 2,926,973; Abstain 121,836; quorum established with 10,193,242 shares present out of 26,585,258 shares entitled to vote.
• An adjournment proposal was approved but not utilized (For 7,279,350; Against 2,866,941; Abstain 46,951).
• The company announced two presentations at CTAD 2025 (Dec 1–4, San Diego), including Phase 2 MINDFuL trial results for XPro1595 (pegipanermin) and a poster on validation of the EMACC cognitive composite.

Sentiment

Score: 5

Explanation: Neutral overall: the option repricing may aid retention but carries dilution optics; upcoming CTAD presentations provide catalysts, balanced by funding and development risks explicitly noted.

Positives

• Shareholders approved the one-time option repricing, providing clearer retention and incentive alignment for employees and directors.
• Repriced exercise price set at the market close ($1.50) on the effective date, aligning incentives with current trading levels.
• Quorum achieved with 10,193,242 shares present, confirming adequate shareholder participation.
• Near-term scientific catalysts with two CTAD 2025 presentations, including Phase 2 MINDFuL results for XPro1595.

Negatives

• Repricing may be viewed as shareholder-unfriendly and could increase potential dilution as up to 5,511,000 options move closer to being in-the-money.
• The repricing covers options held by executive officers and directors, which can draw governance scrutiny.
• No new financial results, revenue, or profitability metrics were disclosed.

Risks

• Ability to produce additional drug supply for clinical trials remains uncertain.
• Availability of substantial additional funding is required to continue operations, R&D, clinical studies, and potential commercialization.
• Regulatory approvals are not assured for CORDStrom, XPro1595 (pegipanermin), or INKmune.
• Clinical trials are early-stage or ongoing; actual outcomes and timing may differ materially from expectations.

Future Outlook

Near term catalysts include two CTAD 2025 presentations, notably Phase 2 MINDFuL results for XPro1595. Management cautions that continued development depends on drug supply and substantial additional funding, and that regulatory approval timelines and outcomes are uncertain.

Management Comments

• Announced that two Alzheimer’s-focused presentations, including Phase 2 MINDFuL trial results for XPro1595, will be delivered at CTAD 2025.
• Confirmed a one-time option repricing to $1.50 per share for eligible employee and director options, with all other option terms unchanged.

Industry Context

Option repricing is a common retention tool among small- and mid-cap biotechs during periods of depressed share prices. Presenting Phase 2 Alzheimer’s data at CTAD is a standard venue for visibility; however, the program remains much earlier than approved anti-amyloid therapies, reflecting higher development and regulatory risk.

Comparison to Industry Standards

• Equity compensation: One-time repricings at market price are used by biotech peers to retain staff after share price declines; this aligns with practices seen across small-cap R&D-stage companies.
• Clinical visibility: Presenting Phase 2 data at CTAD is consistent with industry norms for Alzheimer’s programs; companies like Acumen, Alzheon, and others use CTAD for similar data disclosures.
• Competitive landscape: INmune’s XPro1595 (soluble TNF targeting) is mechanistically distinct from late-stage and approved anti-amyloid antibodies (e.g., Eisai/Biogen’s lecanemab, Eli Lilly’s donanemab), which have set efficacy and safety benchmarks but differ in modality and development maturity.
• Stage of development: Relative to industry leaders with approved or Phase 3 assets, a Phase 2 program carries higher clinical and regulatory uncertainty, consistent with small-cap biotech risk profiles.

Corporate Governance

Related Party Transactions

• Repricing includes options held by executive officers and members of the Board of Directors.

Stakeholder Impact

• Shareholders: Potential dilution and governance optics from repricing up to 5,511,000 options to $1.50.
• Employees and Executives: Improved retention incentives and alignment with current market price.
• Board of Directors: Participation in repricing may draw governance scrutiny but aligns director incentives with shareholders.
• Patients and Clinicians: Upcoming CTAD presentations may inform clinical community on XPro1595 and cognitive endpoints.

Next Steps

• Implement the option repricing for eligible options effective November 18, 2025.
• Present MINDFuL Phase 2 results (Poster P057) at CTAD on Dec 1–2, 2025.
• Present EMACC validation (Poster P316) at CTAD on Dec 4, 2025.

Key Dates

Recommendation

The action is governance- and compensation-focused with limited immediate financial impact; while repricing aids retention, it raises dilution concerns. CTAD presentations provide near-term catalysts, but with no efficacy or financial data disclosed here and explicit funding and development risks, a neutral stance is prudent pending clinical readouts and financing visibility.

Keywords

INmune Bio, option repricing, XPro1595, pegipanermin, MINDFuL trial, CTAD 2025, Alzheimer’s disease, soluble TNF, stock options, shareholder vote, Nasdaq Capital Market, EMACC, INKmune, CORDStrom